Recent Posts

1. 

   Why so many openings

   Options and restricted share incentive programs are all under water, with price volatility so awful that no one thinks there is an upside. The only pharma I know that got an approval and the share price went into the toilet. What a shit show

   Lexicon Pharmaceuticals

   anonymous

   Apr 25, 2024 at 12:52 PM

2. 

   The stock price

   How Count Chocula is still the CEO is mind- numbing to me. We aren’t circling the drain, we are in the drain!

   Pfizer

   anonymous

   Apr 25, 2024 at 12:48 PM

3. 

   What is Acumed thinking?

   Stay ready, Sales! Quotas go up even as products break and the discuss the "R" word. All the experienced engineers and leadership at OsteoMed was let go. Now the internal team is in a spiral trying to "fix it". They had the solutions at OsteoMed...

   Acumed

   anonymous

   Apr 25, 2024 at 12:41 PM

4. 

   Sub $45

   Over the past 12 months BMY has lost approximately $50 billion in market share value. Heads need to roll!!

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 12:39 PM

5. 

   Paragon 28

   I heard the will be bought soon

   Zimmer

   anonymous

   Apr 25, 2024 at 12:33 PM

6. 

   Sandrine & Johanna hire another female.

   Weird phenomenon to have one gender continually be in charge.

   Gilead Sciences

   anonymous

   Apr 25, 2024 at 12:30 PM

7. 

   BMS to cut 2,200 jobs in $1.5B restructuring as Opdivo sales drop in Q1

   via Bristol Myers Squibb revealed in its first-quarter 2024 earnings report on Thursday that it will implement a sweeping “strategic productivity initiative” in a bid to generate approximately $1.5 billion in cost savings through 2025, including...

   Pharma/Biotech Companies - In the News

   cafead

   Apr 25, 2024 at 12:22 PM

8. + Show More